Tejas Patil: First patient with mNSCLC with an EGFR-ERBB4 gene fusion who clinically and radiographically responded to EGFR TKIs
Tejas Patil, Thoracic oncologist at University of Colorado Cancer Center, shared a post on X:
“Along with my CU Cancer Center colleagues, I’m very proud to present the FIRST case of a patient with metastatic NSCLC with an EGFR-ERBB4 gene fusion who clinically and radiographically responded to sequential EGFR TKIs, now published in JCO Precision Oncology.
Key points:
Point 1: ERBB4 fusions represent 0.1% of all ERBB fusions. In a prior study, EGFR::ERBB4 cancer cells treated with EGFR TKIs including osimertinib and tarloxotinib, had decreased levels of activated EGFR, ERBB4, and downstream signaling proteins.
Point 2: RNA-based fusion testing in our pt revealed an in-frame transcript between EGFR exon 25 and ERBB4 exon 18. Shows importance of RNA NGS for gene fusions in NSCLC! This fusion product is anticipated to juxtapose the TKDs while conserving ERBB4 protein interaction motifs.
Point 3: Pt was HEAVILY pre-treated with complex course. Received mobocertinib (compassionate access) because of insurance coverage issues. Had CNS progression on mobo, which prompted switch to osimertinib. Remains on therapy with excellent treatment response to this day.
Authors: Amy Guimaraes-Young, Kurtis D. Davies, Patricia Trevisan, Hala Nijmeh, Mary Haag, Dara L. Aisner, and Tejas Patil
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023